Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Donafenib plus toripalimab in second-line extensive-stage small cell lung cancer
ChiCTR2100044790Phase 2Recruiting
- Sponsor
- Chinese PLA General Hospital
- Start
- Apr 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of donafenib and toripalimab in small cell lung cancer (SCLC) (2 arms), sponsored by Chinese PLA General Hospital. Primary endpoint: Objective response rate. Started Apr 2021; status: recruiting.
02
Drugs
donafenibtoripalimab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on ChiCTR2100044790.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100044790.